Mylan tapped as Gilead's exclusive business partner for India

PITTSBURGH and MUMBAI, India — Mylan announced that its India-based subsidiary, Mylan Pharmaceuticals Private Limited, has been named Gilead Sciences' branded medicines business partner for India.



Under this exclusive agreement, Mylan will market and distribute in India the following drugs from Gilead:

• HIV therapies Viread (tenofovir disoproxil fumarate), Truvada (emtricitabine/tenofovir disoproxil fumarate) and the newer single-tablet regiment Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg);


• AmBisome (amphotericin B liposome for injection), used to treat life-threatening, systemic fungal infections. It's also used to treat the parasitic disease visceral leishmaniasis; and


• Viread for its use as a treatment for chronic hepatitis B virus (HBV) infection.

"This further extension of our collaboration with Gilead builds off of our existing successful partnership manufacturing and supplying high-quality, cost-effective generic antiretroviral therapy for those in resource challenged countries, delivering on our mission of providing access to high quality medicine to the world's seven billion people," Mylan CEO Heather Bresch said.



Mylan was selected in September 2012 as a leading supplier of antiretroviral medication to India's National AIDS Control Organization. India is home to the world's largest-population of people with HIV/AIDS, with approximately 2.4 million people living with the disease.